This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wotton, S. Articles by Cameron, E. R. Search for Related Content PubMed PubMed Citation Articles by Wotton, S. Articles by Cameron, E. R.

Proviral Insertion Indicates a Dominant Oncogenic Role for Runx1/AML-1 in T-Cell Lymphoma¹

Molecular Oncology Laboratory, Institute of Comparative Medicine, University of Glasgow Veterinary School, Glasgow G61 1QH, United Kingdom

The RUNX1/AML1 gene is a frequent target for chromosomal translocations in human leukemia. The biological properties of the resulting fusion products and the finding that haploinsufficiency increases the risk of developing leukemia (W-J. Song et al., Nat. Genet., 23: 166–175, 1999; M. Osata et al., Blood, 93: 1817–1824, 1999) have led to the widely held view that RUNX1 loss-of-function is a key event. However, we now report that the gene is a target for insertional mutagenesis in T-cell lymphomas of mice carrying a MYC oncogene, where promoter insertion results in overexpression without affecting the integrity of the coding sequence. Moreover, Runx1 haploinsufficiency does not accelerate lymphoma development in MYC/Runx2 transgenic or murine leukemia virus-infected mice. These findings reveal that the Runx1 gene can also act as a dominant oncogene and suggest that the involvement of the Runx gene family in human leukemia may be more widespread and complex than previously realized.

This article has been cited by other articles:

				Y.-H. Kuo, S. K. Zaidi, S. Gornostaeva, T. Komori, G. S. Stein, and L. H. Castilla Runx2 induces acute myeloid leukemia in cooperation with Cbf{beta}-SMMHC in mice Blood, April 2, 2009; 113(14): 3323 - 3332. [Abstract] [Full Text] [PDF]

				A. Kilbey, K. Blyth, S. Wotton, A. Terry, A. Jenkins, M. Bell, L. Hanlon, E. R. Cameron, and J. C. Neil Runx2 Disruption Promotes Immortalization and Confers Resistance to Oncogene-Induced Senescence in Primary Murine Fibroblasts Cancer Res., December 1, 2007; 67(23): 11263 - 11271. [Abstract] [Full Text] [PDF]

				M. Stewart, N. Mackay, L. Hanlon, K. Blyth, L. Scobie, E. Cameron, and J. C. Neil Insertional Mutagenesis Reveals Progression Genes and Checkpoints in MYC/Runx2 Lymphomas Cancer Res., June 1, 2007; 67(11): 5126 - 5133. [Abstract] [Full Text] [PDF]

				K. Blyth, F. Vaillant, L. Hanlon, N. Mackay, M. Bell, A. Jenkins, J. C. Neil, and E. R. Cameron Runx2 and MYC Collaborate in Lymphoma Development by Suppressing Apoptotic and Growth Arrest Pathways In vivo Cancer Res., February 15, 2006; 66(4): 2195 - 2201. [Abstract] [Full Text] [PDF]

				T. E. North, T. Stacy, C. J. Matheny, N. A. Speck, and M. F.T.R. de Bruijn Runx1 Is Expressed in Adult Mouse Hematopoietic Stem Cells and Differentiating Myeloid and Lymphoid Cells, But Not in Maturing Erythroid Cells Stem Cells, March 1, 2004; 22(2): 158 - 168. [Abstract] [Full Text] [PDF]

				B. A. Hug, N. Ahmed, J. A. Robbins, and M. A. Lazar A Chromatin Immunoprecipitation Screen Reveals Protein Kinase C{beta} as a Direct RUNX1 Target Gene J. Biol. Chem., January 9, 2004; 279(2): 825 - 830. [Abstract] [Full Text] [PDF]